Glenmark Pharmaceuticals is set to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial in the US market.

The product is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443.

Glenmark plans to begin distribution in November 2025. According to IQVIA sales data for the 12 months ending August 2025, the US market for 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) was valued at approximately USD 63.8 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are pleased to announce the expansion of our injectable portfolio to include the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, which further reinforces our dedication to bring quality and affordable alternatives to market to patients in need.”

Headquartered in Mumbai, Glenmark Pharmaceuticals is a research?led, global pharmaceutical company with a presence across branded, generics and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology and oncology, and operates 11 world-class manufacturing facilities across four continents, and has a footprint in over 80 countries.